About the Company
We do not have any company description for IN8BIO, INC. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on IN8BIO, INC.
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient ...
IN8bio, Inc. (NASDAQ:INAB) insider upped their holding by 3.0% earlier ...
Insiders were net buyers of IN8bio, Inc.'s (NASDAQ:INAB ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important ...
In8bio, Inc. Reports Improved Financial Performance
In8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for unmet medical needs, particularly in the field of oncology. The company is actively ...
IN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2024 Financial ...
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial ...
IN8bio, Inc. (INAB) latest stock news and headlines – Yahoo Finance
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ...
Trade Alert: The Independent Director Of IN8bio, Inc. (NASDAQ:INAB ...
IN8bio, Inc. (NASDAQ:INAB) shareholders (or potential shareholders) will be happy to see that the Independent Director, Emily Fairbairn, recently bought a whopping US$1.5m worth of stock, at a ...
IN8bio, Inc: IN8bio Recognizes Achievement of 4-Years in Remission for ...
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
How IN8bio Is Working To Reach Its Goal Of "Cancer Zero" – Making ...
IN8bio Inc.INAB is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate ...
Incysus Therapeutics Announces Name Change to IN8bio, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (γδ) T cell immunotherapies for ...
IN8bio Shares Are Pulling Back Tuesday: What's Going On?
IN8bio Inc (NASDAQ: INAB) shares are trading lower Tuesday on what appears to be profit taking after the stock rallied 185% on Monday.
IN8bio, Inc. (INAB) Latest Stock News & Headlines - Yahoo Finance
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ...
IN8bio, Inc. (6JH.F) Latest Stock News & Headlines - Yahoo Finance
IN8bio Announces Pricing of $12.4 Million Private Placement Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion cohorts ...
Similar Companies
Loading the latest forecasts...